# A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

> **NCT01654536** · PHASE4 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 737 (actual)

## Conditions studied

- Perennial Allergic Rhinitis

## Interventions

- **DRUG:** ciclesonide nasal aerosol
- **DRUG:** ciclesonide nasal spray

## Key facts

- **NCT ID:** NCT01654536
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 737 (ACTUAL)
- **Last updated:** 2014-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01654536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01654536, "A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01654536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*